NAD+
Metabolic and Mitochondrial
£55.00per vial
NAD+ is the redox coenzyme that carries hydride between NAD+ and NADH, and the substrate consumed by sirtuins, PARP enzymes, and CD38 in NAD-dependent reactions. It is a dinucleotide, not a peptide. It is catalogued for in-vitro work on mitochondrial bioenergetics, NAD+/NADH ratio measurement, and salvage-pathway kinetics.
For laboratory research only. Not for human consumption. No medical claims. This product is not intended to diagnose, treat, cure, or prevent any disease.
This vial is sealed for the protection of health and hygiene. Under regulation 28(1)(e) of the Consumer Contracts (Information, Cancellation and Additional Charges) Regulations 2013, the 14-day right to cancel is lost for this item once that seal is broken. While the seal is intact the right applies in full.
NAD+ cannot be listed to research users in Australia, Canada, Japan, Mexico, New Zealand, Norway, Russian Federation, Saudi Arabia, Singapore, South Korea, Switzerland, United Arab Emirates. Verify local eligibility before ordering.
Listed
- Molecular weight
- 663.4 g/mol
- Presentation
- Pre-mixed solution, 3ml vial
For laboratory research only. Not for human consumption. No medical claims.
- UK DISPATCH
- TRACKED SHIPPING
- COA PER BATCH
- SECURE PAYMENT
§01Compound Profile
Every batch is independently analysed by HPLC and mass spectrometry before it is listed, and the Certificate of Analysis for that batch is published in full, including the measured purity figure for that batch.
HPLC
Purity by chromatography
ANALYSED
MASS SPECTROMETRY
Identity confirmation
ANALYSED
PUBLIC COA
Every batch number resolves to its Certificate of Analysis
DOCUMENTED
§02The Science
Published constants and presentation for NAD+, as catalogued.
Every figure in this list is a published constant or a presentation fact. None of it is an analytical result: the measured figures live on the Certificate of Analysis for the batch.
- Molecular weight
- 663.4 g/mol
- Presentation
- Pre-mixed solution, 3ml vial
- Batch reference
- ND5606
Molecular weight source: PubChem CID 5892 (nadide).
§03Certificate of Analysis
Every batch is independently analysed by HPLC and mass spectrometry before it is listed, and the Certificate of Analysis for that batch is published in full, including the measured purity figure for that batch.
| PARAMETER | METHOD | RESULT |
|---|---|---|
| Purity | HPLC | 98.8% |
| Identity | Mass spectrometry | Confirmed |
ND5606 · 2026-06-16
§04Compound details
NAD+ (nicotinamide adenine dinucleotide) sits at the centre of cellular redox chemistry. In its oxidised form it accepts a hydride ion to become NADH, and that couple carries reducing equivalents from glycolysis, the tricarboxylic acid cycle, and beta-oxidation into complex I of the electron transport chain. The cytosolic and mitochondrial pools are compartmentalised and are shuttled rather than mixed, which is why NAD+/NADH ratio measurement is treated as a compartment-specific readout in laboratory work rather than a single whole-cell number.
Beyond redox carrying, NAD+ is consumed as a substrate. Sirtuins (SIRT1 through SIRT7) cleave NAD+ to deacetylate lysine residues on histones and metabolic enzymes, producing nicotinamide and 2-O-acetyl-ADP-ribose. PARP1 and PARP2 consume NAD+ to build poly(ADP-ribose) chains at sites of DNA strand breaks. CD38 hydrolyses NAD+ to generate cyclic ADP-ribose. Each of these reactions draws on the same pool, which is why NAD+ availability is studied as a coupling point between metabolic state and gene regulation.
Controlled laboratory investigation of NAD+ concentrates on the salvage pathway, in which nicotinamide phosphoribosyltransferase (NAMPT) recycles nicotinamide back into NMN and then NAD+, and on how pool depletion under replicative or genotoxic stress alters sirtuin and PARP activity in cell and tissue models. It is frequently run in parallel with precursor compounds so that flux through the salvage route can be traced rather than inferred. No therapeutic, diagnostic, or clinical conclusion is drawn from any study referenced above, and none should be inferred.
NAD+ is listed as a pre-mixed solution in a sealed 3ml vial, at 500mg and 1000mg. It requires no reconstitution and no diluent.
Every batch is independently analysed before it is listed. Purity is measured by high-performance liquid chromatography. Identity is confirmed by mass spectrometry against the expected mass. Those are the two analytical methods used, and no other method is claimed.
Each vial carries a lot number. That lot number resolves to the public Certificate of Analysis for that batch, published in full, including the raw chromatograms rather than a summary figure, together with the lot reference, the analysis date, and the laboratory that ran it.
Research Use Only
NAD+ is catalogued strictly for in-vitro laboratory research. It is not for human consumption, veterinary use, or therapeutic, diagnostic or clinical application. It is not supplied as a medicinal product and it is not licensed by the MHRA.
Not a Medical Product
None of the compounds listed on this site are medicinal products, nor should they be marketed, described or used as such. No medical claims are made about NAD+. Nothing on this page is medical, veterinary or scientific advice, and no guidance on preparation, administration or quantity is provided or will be provided on request.
Compliance and Responsibility
The research user is responsible for ensuring compliance with all laws and regulations governing the receipt, handling, storage, use and disposal of research chemicals in their jurisdiction, and for applying appropriate control measures under the Control of Substances Hazardous to Health Regulations 2002 or the equivalent local regime.
Analytical Scope
Analytical results published for NAD+ relate solely to the batch identified on the Certificate of Analysis. Two methods are used: high-performance liquid chromatography and mass spectrometry. No other analysis is performed or implied. Results for one batch do not warrant any other batch.
Jurisdiction Notice
NAD+ cannot be listed to research users in the following jurisdictions: Australia, Canada, Japan, Mexico, New Zealand, Norway, Russian Federation, Saudi Arabia, Singapore, South Korea, Switzerland, United Arab Emirates. It is the research user's responsibility to verify local eligibility before placing an order. Where an order is placed for a jurisdiction in which the compound cannot be listed, the order will be cancelled and refunded in full.
Research Context
NAD+ (nicotinamide adenine dinucleotide) sits at the centre of cellular redox chemistry. In its oxidised form it accepts a hydride ion to become NADH, and that couple carries reducing equivalents from glycolysis, the tricarboxylic acid cycle, and beta-oxidation into complex I of the electron transport chain. The cytosolic and mitochondrial pools are compartmentalised and are shuttled rather than mixed, which is why NAD+/NADH ratio measurement is treated as a compartment-specific readout in laboratory work rather than a single whole-cell number.
Beyond redox carrying, NAD+ is consumed as a substrate. Sirtuins (SIRT1 through SIRT7) cleave NAD+ to deacetylate lysine residues on histones and metabolic enzymes, producing nicotinamide and 2-O-acetyl-ADP-ribose. PARP1 and PARP2 consume NAD+ to build poly(ADP-ribose) chains at sites of DNA strand breaks. CD38 hydrolyses NAD+ to generate cyclic ADP-ribose. Each of these reactions draws on the same pool, which is why NAD+ availability is studied as a coupling point between metabolic state and gene regulation.
Controlled laboratory investigation of NAD+ concentrates on the salvage pathway, in which nicotinamide phosphoribosyltransferase (NAMPT) recycles nicotinamide back into NMN and then NAD+, and on how pool depletion under replicative or genotoxic stress alters sirtuin and PARP activity in cell and tissue models. It is frequently run in parallel with precursor compounds so that flux through the salvage route can be traced rather than inferred. No therapeutic, diagnostic, or clinical conclusion is drawn from any study referenced above, and none should be inferred.
Analysis and Documentation
NAD+ is listed as a pre-mixed solution in a sealed 3ml vial, at 500mg and 1000mg. It requires no reconstitution and no diluent.
Every batch is independently analysed before it is listed. Purity is measured by high-performance liquid chromatography. Identity is confirmed by mass spectrometry against the expected mass. Those are the two analytical methods used, and no other method is claimed.
Each vial carries a lot number. That lot number resolves to the public Certificate of Analysis for that batch, published in full, including the raw chromatograms rather than a summary figure, together with the lot reference, the analysis date, and the laboratory that ran it.
Compliance Notice
Research Use Only
NAD+ is catalogued strictly for in-vitro laboratory research. It is not for human consumption, veterinary use, or therapeutic, diagnostic or clinical application. It is not supplied as a medicinal product and it is not licensed by the MHRA.
Not a Medical Product
None of the compounds listed on this site are medicinal products, nor should they be marketed, described or used as such. No medical claims are made about NAD+. Nothing on this page is medical, veterinary or scientific advice, and no guidance on preparation, administration or quantity is provided or will be provided on request.
Compliance and Responsibility
The research user is responsible for ensuring compliance with all laws and regulations governing the receipt, handling, storage, use and disposal of research chemicals in their jurisdiction, and for applying appropriate control measures under the Control of Substances Hazardous to Health Regulations 2002 or the equivalent local regime.
Analytical Scope
Analytical results published for NAD+ relate solely to the batch identified on the Certificate of Analysis. Two methods are used: high-performance liquid chromatography and mass spectrometry. No other analysis is performed or implied. Results for one batch do not warrant any other batch.
Jurisdiction Notice
NAD+ cannot be listed to research users in the following jurisdictions: Australia, Canada, Japan, Mexico, New Zealand, Norway, Russian Federation, Saudi Arabia, Singapore, South Korea, Switzerland, United Arab Emirates. It is the research user's responsibility to verify local eligibility before placing an order. Where an order is placed for a jurisdiction in which the compound cannot be listed, the order will be cancelled and refunded in full.
§05Related compounds
§06Questions
No. NAD+ is catalogued strictly for in-vitro laboratory research. It is not for human or veterinary consumption and no medical claims are made.
NAD+ is studied as a redox carrier in the electron transport chain and as the consumed substrate of sirtuins, PARP enzymes, and CD38 in cell and tissue models.
Nicotinamide adenine dinucleotide. The plus sign denotes the oxidised form of the couple. The reduced form is NADH.
No. It is a dinucleotide coenzyme, a different compound class from the peptides catalogued alongside it, and it is described as a research compound throughout.
Pre-mixed solution in a sealed 3ml vial, at 500mg and 1000mg. No reconstitution is required.
Every batch has a document.
The Certificate of Analysis for a batch is published when that batch is released. Your batch number resolves to the report.
For laboratory research only. Not for human consumption. No medical claims.
